Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

Amgen (AMGN) announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status.Blincyto, a first-in-class Bispecific T-cell Engager (BiTE) therapy, is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of MRD status. ALL is a fast-growing type of blood ca ...